Your browser doesn't support javascript.
loading
Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy.
Barbour, Sean J; Coppo, Rosanna; Zhang, Hong; Liu, Zhi-Hong; Suzuki, Yusuke; Matsuzaki, Keiichi; Er, Lee; Reich, Heather N; Barratt, Jonathan; Cattran, Daniel C.
Affiliation
  • Barbour SJ; Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada; BC Renal, Vancouver, British Columbia, Canada. Electronic address: sean.barbour@vch.ca.
  • Coppo R; Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy.
  • Zhang H; Peking University Institute of Nephrology, Beijing, China.
  • Liu ZH; Nanjing University School of Medicine, Nanjing, China.
  • Suzuki Y; Faculty of Medicine, Juntendo University, Tokyo, Japan.
  • Matsuzaki K; Faculty of Medicine, Juntendo University, Tokyo, Japan.
  • Er L; BC Renal, Vancouver, British Columbia, Canada.
  • Reich HN; Division of Nephrology, University of Toronto, Toronto, Ontario, Canada.
  • Barratt J; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
  • Cattran DC; Division of Nephrology, University of Toronto, Toronto, Ontario, Canada. Electronic address: daniel.cattran@uhn.ca.
Kidney Int ; 102(1): 160-172, 2022 07.
Article in En | MEDLINE | ID: mdl-35490842
ABSTRACT
The International IgA Nephropathy (IgAN) Prediction Tool is the preferred method in the 2021 KDIGO guidelines to predict, at the time of kidney biopsy, the risk of a 50% drop in estimated glomerular filtration rate or kidney failure. However, it is not known if the Prediction Tool can be accurately applied after a period of observation post-biopsy. Using an international multi-ethnic derivation cohort of 2,507 adults with IgAN, we updated the Prediction Tool for use one year after biopsy, and externally validated this in a cohort of 722 adults. The original Prediction Tool applied at one-year without modification had a coefficient of variation (R2) of 55% and 54% and four-year concordance (C statistic) of 0.82 but poor calibration with under-prediction of risk (integrated calibration index (ICI) 1.54 and 2.11, with and without race, respectively). Our updated Prediction Tool had a better model fit with higher R2 (61% and 60%), significant increase in four-year C-statistic (0.87 and 0.86) and better four-year calibration with lower ICI (0.75 and 0.35). On external validation, the updated Prediction Tool had similar R2 (60% and 58%) and four-year C-statistics (both 0.85) compared to the derivation analysis, with excellent four-year calibration (ICI 0.62 and 0.56). This updated Prediction Tool had similar prediction performance when used two years after biopsy. Thus, the original Prediction Tool should be used only at the time of biopsy whereas our updated Prediction Tool can be used for risk stratification one or two years post-biopsy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Renal Insufficiency / Glomerulonephritis, IGA Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Kidney Int Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Renal Insufficiency / Glomerulonephritis, IGA Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Kidney Int Year: 2022 Document type: Article